Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Proliferative retinopathy in Duchenne muscular dystrophy and its response to bevacizumab.

Fagan XJ, Levy J, Al-Qureshi S, Harper CA.

Clin Exp Ophthalmol. 2012 Dec;40(9):906-7. doi: 10.1111/j.1442-9071.2012.02822.x. No abstract available.

PMID:
22594924
2.

Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naïve proliferative and severe nonproliferative diabetic retinopathy.

Ernst BJ, García-Aguirre G, Oliver SC, Olson JL, Mandava N, Quiroz-Mercado H.

Acta Ophthalmol. 2012 Nov;90(7):e573-4. doi: 10.1111/j.1755-3768.2011.02364.x. Epub 2012 Mar 9. No abstract available.

3.

Long term result of intravitreal bevacizumab in a patient newly transformed to proliferative macular telangiectasia type 2.

Ozkaya A, Alkin Z, Karakucuk Y, Yazici AT, Demirok A.

Middle East Afr J Ophthalmol. 2013 Oct-Dec;20(4):360-2. doi: 10.4103/0974-9233.120005.

4.

Reduction in dose of intravitreous bevacizumab before vitrectomy for proliferative diabetic retinopathy.

Yamaji H, Shiraga F, Shiragami C, Nomoto H, Fujita T, Fukuda K.

Arch Ophthalmol. 2011 Jan;129(1):106-7. doi: 10.1001/archophthalmol.2010.333. No abstract available.

PMID:
21220639
5.

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.

Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A.

Ophthalmology. 2006 Oct;113(10):1695.e1-15.

PMID:
17011951
6.

Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia.

Roller AB, Folk JC, Patel NM, Boldt HC, Russell SR, Abramoff MD, Mahajan VB.

Retina. 2011 Oct;31(9):1848-55. doi: 10.1097/IAE.0b013e31820d3feb.

PMID:
21610563
7.

What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?

Spandau U.

Acta Ophthalmol. 2013 Mar;91(2):e154. doi: 10.1111/j.1755-3768.2012.02552.x. Epub 2012 Sep 19. No abstract available.

8.

Exudative retinal astrocytic hamartoma diagnosed and treated with pars plana vitrectomy and intravitreal bevacizumab.

Nakayama M, Keino H, Hirakata A, Okada AA, Terado Y.

Eye (Lond). 2012 Sep;26(9):1272-3. doi: 10.1038/eye.2012.124. Epub 2012 Jun 22. No abstract available.

9.

Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies.

Park SW, Jung HH, Heo H.

Acta Ophthalmol. 2014 Dec;92(8):810-3. doi: 10.1111/aos.12461. Epub 2014 Jun 9. No abstract available.

10.

Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization.

Soliman W, Lund-Andersen H, Larsen M.

Acta Ophthalmol Scand. 2006 Oct;84(5):707-8. No abstract available.

11.

Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy.

Henaine-Berra A, Garcia-Aguirre G, Quiroz-Mercado H, Martinez-Castellanos MA.

J AAPOS. 2014 Apr;18(2):120-3. doi: 10.1016/j.jaapos.2013.12.009.

PMID:
24698606
12.

Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.

Spandau UH, Jonas JB.

Acta Ophthalmol Scand. 2007 May;85(3):340-1. No abstract available.

13.

Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.

Schmidinger G, Maar N, Bolz M, Scholda C, Schmidt-Erfurth U.

Acta Ophthalmol. 2011 Feb;89(1):76-81. doi: 10.1111/j.1755-3768.2009.01622.x.

14.

Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2.

Narayanan R, Chhablani J, Sinha M, Dave V, Tyagi M, Pappuru RR, Kuppermann BD.

Retina. 2012 Nov-Dec;32(10):2001-5. doi: 10.1097/IAE.0b013e3182625c1d.

PMID:
22990322
15.

RANDOMIZED CONTROLLED STUDY OF INTRAVITREAL BEVACIZUMAB 0.16 MG INJECTED ONE DAY BEFORE SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY.

Manabe A, Shimada H, Hattori T, Nakashizuka H, Yuzawa M.

Retina. 2015 Sep;35(9):1800-7. doi: 10.1097/IAE.0000000000000577.

PMID:
25932549
16.

Use of intravitreal bevacizumab injections to treat type 1 idiopathic macular telangiectasia.

Moon BG, Kim YJ, Yoon YH, Lee JY.

Graefes Arch Clin Exp Ophthalmol. 2012 Nov;250(11):1697-9. doi: 10.1007/s00417-011-1798-2. Epub 2011 Aug 24. No abstract available.

PMID:
21863255
17.

Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.

Yang CS, Hung KC, Huang YM, Hsu WM.

J Ocul Pharmacol Ther. 2013 Jul-Aug;29(6):550-5. doi: 10.1089/jop.2012.0202. Epub 2013 Mar 15.

18.

Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.

Tatlipinar S, Dinç UA, Yenerel NM, Görgün E.

Clin Exp Optom. 2012 Jan;95(1):94-8. doi: 10.1111/j.1444-0938.2011.00662.x. Epub 2011 Sep 28.

20.

Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy.

Siqueira RC, Costa RA, Scott IU, Cintra LP, Jorge R.

Acta Ophthalmol Scand. 2006 Dec;84(6):834-5. No abstract available.

Supplemental Content

Support Center